Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY | Market Cap | 6.29T |
| Revenue (ttm) | 4.58T |
| Net Income (ttm) | 107.93B |
| Shares Out | 1.57B |
| EPS (ttm) | 67.23 |
| PE Ratio | 59.50 |
| Forward PE | 30.31 |
| Dividend | 200.00 (4.72%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 13,248,400 |
| Average Volume | 5,430,010 |
| Open | 4,027.00 |
| Previous Close | 4,234.00 |
| Day's Range | 4,000.00 - 4,074.00 |
| 52-Week Range | 3,852.00 - 4,573.00 |
| Beta | 0.26 |
| RSI | 35.75 |
| Earnings Date | May 8, 2025 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Financial Performance
In 2024, TYO:4502's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.
Financial StatementsNews
Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise
Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript
Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO
Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug...
Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO
Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug...
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
Takeda Pharmaceutical Company Limited (NYSE: TAK) reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year . Core net profit increased 2.5% (dow...
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
Takeda Pharmaceutical Company Limited TAK reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year.
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...
Takeda Pharmaceutical Non-GAAP EPS of ¥491.00, revenue of ¥4581.6B; initiates FY25 outlook
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Produ...
Takeda Pharmaceutical FY Earnings Preview
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
BANNOCKBURN, Ill.--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. ...
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
How Takeda's CEO transformed the company into a global pharma powerhouse
Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies.
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas...
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Ico...
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they h...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
On Monday, Protagonist Therapeutics, Inc. (NASDAQ: PTGX) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera . Poly...
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results ...
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE. 1 The Pre-Filled P...
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pe...
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge
BOSTON--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architect...
Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO
Earnings Scheduled For January 30, 2025
Companies Reporting Before The Bell • Northrop Grumman (NYSE: NOC) is likely to report quarterly earnings at $6.35 per share on revenue of $10.97 billion. • Mobileye Global (NASDAQ: MBLY) is project...